Molecular phenotyping of clinical AKI with novel urinary biomarkers

Sarah Huen, Chirag R. Parikh

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Acute kidney injury (AKI) is a common hospital complication. There are no effective treatments to minimize kidney injury or limit associated morbidity and mortality. Currently, serum creatinine and urine output remain the gold standard used clinically in the diagnosis of AKI. Several novel biomarkers can diagnose AKI earlier than elevations of serum creatinine and changes in urine output. Recent long-term observational studies have elucidated a subgroup of patients who have positive biomarkers of AKI but do not meet criteria for AKI by serum creatinine or urine output, termed subclinical AKI. These patients with subclinical AKI have increased risk of both short- and long-term mortality. In this review, we will highlight the implications of what these patients may represent and the need for better phenotyping of AKI by etiology, severity of injury, and ability to recover. We will discuss two AKI biomarkers, neutrophil gelatinase-associated lipocalin (NGAL) and breast regression protein-39 (BRP-39)/YKL-40, that exemplify the need to characterize the complexity of the biological meaning behind the biomarker, beyond elevated levels reporting on tissue injury. Ultimately, careful phenotyping of AKI will lead to identification of therapeutic targets and appropriate patient populations for clinical trials.

Original languageEnglish (US)
Pages (from-to)F406-F413
JournalAmerican Journal of Physiology - Renal Physiology
Volume309
Issue number5
DOIs
StatePublished - Jan 1 2015

Fingerprint

Acute Kidney Injury
Biomarkers
Creatinine
Urine
Wounds and Injuries
Serum
Mortality
Observational Studies
Breast
Clinical Trials
Morbidity
Kidney
Therapeutics

Keywords

  • Chitinase 3-like 1
  • Heterogeneity
  • NGAL
  • Outcomes
  • Subclinical injury

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

Molecular phenotyping of clinical AKI with novel urinary biomarkers. / Huen, Sarah; Parikh, Chirag R.

In: American Journal of Physiology - Renal Physiology, Vol. 309, No. 5, 01.01.2015, p. F406-F413.

Research output: Contribution to journalReview article

@article{9fb0f611c9234dc186496e6c9373ad2f,
title = "Molecular phenotyping of clinical AKI with novel urinary biomarkers",
abstract = "Acute kidney injury (AKI) is a common hospital complication. There are no effective treatments to minimize kidney injury or limit associated morbidity and mortality. Currently, serum creatinine and urine output remain the gold standard used clinically in the diagnosis of AKI. Several novel biomarkers can diagnose AKI earlier than elevations of serum creatinine and changes in urine output. Recent long-term observational studies have elucidated a subgroup of patients who have positive biomarkers of AKI but do not meet criteria for AKI by serum creatinine or urine output, termed subclinical AKI. These patients with subclinical AKI have increased risk of both short- and long-term mortality. In this review, we will highlight the implications of what these patients may represent and the need for better phenotyping of AKI by etiology, severity of injury, and ability to recover. We will discuss two AKI biomarkers, neutrophil gelatinase-associated lipocalin (NGAL) and breast regression protein-39 (BRP-39)/YKL-40, that exemplify the need to characterize the complexity of the biological meaning behind the biomarker, beyond elevated levels reporting on tissue injury. Ultimately, careful phenotyping of AKI will lead to identification of therapeutic targets and appropriate patient populations for clinical trials.",
keywords = "Chitinase 3-like 1, Heterogeneity, NGAL, Outcomes, Subclinical injury",
author = "Sarah Huen and Parikh, {Chirag R.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1152/ajprenal.00682.2014",
language = "English (US)",
volume = "309",
pages = "F406--F413",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "5",

}

TY - JOUR

T1 - Molecular phenotyping of clinical AKI with novel urinary biomarkers

AU - Huen, Sarah

AU - Parikh, Chirag R.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Acute kidney injury (AKI) is a common hospital complication. There are no effective treatments to minimize kidney injury or limit associated morbidity and mortality. Currently, serum creatinine and urine output remain the gold standard used clinically in the diagnosis of AKI. Several novel biomarkers can diagnose AKI earlier than elevations of serum creatinine and changes in urine output. Recent long-term observational studies have elucidated a subgroup of patients who have positive biomarkers of AKI but do not meet criteria for AKI by serum creatinine or urine output, termed subclinical AKI. These patients with subclinical AKI have increased risk of both short- and long-term mortality. In this review, we will highlight the implications of what these patients may represent and the need for better phenotyping of AKI by etiology, severity of injury, and ability to recover. We will discuss two AKI biomarkers, neutrophil gelatinase-associated lipocalin (NGAL) and breast regression protein-39 (BRP-39)/YKL-40, that exemplify the need to characterize the complexity of the biological meaning behind the biomarker, beyond elevated levels reporting on tissue injury. Ultimately, careful phenotyping of AKI will lead to identification of therapeutic targets and appropriate patient populations for clinical trials.

AB - Acute kidney injury (AKI) is a common hospital complication. There are no effective treatments to minimize kidney injury or limit associated morbidity and mortality. Currently, serum creatinine and urine output remain the gold standard used clinically in the diagnosis of AKI. Several novel biomarkers can diagnose AKI earlier than elevations of serum creatinine and changes in urine output. Recent long-term observational studies have elucidated a subgroup of patients who have positive biomarkers of AKI but do not meet criteria for AKI by serum creatinine or urine output, termed subclinical AKI. These patients with subclinical AKI have increased risk of both short- and long-term mortality. In this review, we will highlight the implications of what these patients may represent and the need for better phenotyping of AKI by etiology, severity of injury, and ability to recover. We will discuss two AKI biomarkers, neutrophil gelatinase-associated lipocalin (NGAL) and breast regression protein-39 (BRP-39)/YKL-40, that exemplify the need to characterize the complexity of the biological meaning behind the biomarker, beyond elevated levels reporting on tissue injury. Ultimately, careful phenotyping of AKI will lead to identification of therapeutic targets and appropriate patient populations for clinical trials.

KW - Chitinase 3-like 1

KW - Heterogeneity

KW - NGAL

KW - Outcomes

KW - Subclinical injury

UR - http://www.scopus.com/inward/record.url?scp=84940863941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940863941&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00682.2014

DO - 10.1152/ajprenal.00682.2014

M3 - Review article

VL - 309

SP - F406-F413

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 5

ER -